Immunomodulatory Activity of Oligopeptides Related to Interleukin 1 Receptor Antagonist Sequence

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 5-6, 1997, Pages 427-433

  Kluczyk, Alicja ^a   Siemion, Ignacy Z ^a   Słoń Usakiewicz, Jacek J ^a   Wieczorek, Zbigniew ^b  

^a UNIVERSITY OF WROC AW   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Immune response; Interleukin 1 receptor antagonist; Thymopentin; Tuftsin

Indexed keywords

IL1RN PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OLIGOPEPTIDE; SIALOGLYCOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HEMOLYTIC PLAQUE ASSAY; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; PHYSIOLOGY; SHEEP; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ERYTHROCYTES; FEMALE; GRAFT VS HOST REACTION; HEMOLYTIC PLAQUE TECHNIQUE; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; RECEPTORS, INTERLEUKIN-1; SHEEP; SIALOGLYCOPROTEINS;

EID: 0031306963     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. DEBETS R. and S̀AVALKOUL F. J. (1994): Cytokine antagonists and their potential therapeutic use. Immunol. Today, 15, 455-458.
2. DINARELLO C. A. (1994): Interleukin-1. In THOMPSON A.: The cytokine handbook. Academic Press, London, 2nd ed., 31-56.
3. DINARELLO C. A. and THOMPSON R. C. (1991): Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today, 12, 404-410.
4. FAHERTY D. A., CLAUDY V., PLOCINSKI J. M., KAFFKA K., KILIAN P., THOMPSON R. C. and BENJAMIN W. R. (1992): Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J. Immunol., 148, 766-771.
5. GOLDSTEIN G., SCHEIDL M. P., BOYSE E. A., SCHLESINGER D. H. and VANWAUWE J. (1979): A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science, 204, 1309-1310.
6. GRÜTTER M. G., VAN OOSTRUM J., PRIESTLE J. P., EDELMANN E., JOSS U., FEIGE U., VOSBECK K. and SCHMITZ A. (1994): A mutational analysis of receptor binding sites of interleukin-1β: differences in binding of human interleukin-1β muteins to human and mouse receptors. Protein Eng., 7, 663-671.
7. JU G., LABRIOLA-TOMPKINS E., CAMPEN C. A., BENJAMIN W. R., KARAS J., PLOCINSKI J., BIONDI D., KAFFKA K. L., KILIAN P. L., EISENBERG S. P. and EVANS R. J. (1991): Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc. Natl. Acad. Sci. USA, 88, 2658-2662.
8. KROEMER G. and MARTINEZ-A. C. (1992): Introduction: Cytokines and autoimmunity. Semin. Immunol., 4, 129-131.
9. LAGRANGE P. H., MACKSANESS G. B., MILLER T. E. and PARDON P. (1974): Influence of dose and route of antigen injection on the immunological induction of T cells. J. Exp. Med., 139, 528-542.
10. LENNARD A. C. (1995): Interleukin-1 receptor antagonist. Crit. Rev. Immunol., 15, 77-105.
11. MCCARTHY P. L. JR., ABHYANKAR S., NEBEN S., NEWMAN G., SIEFF C., THOMPSON R. C., BURAKOFF S. J. and FERRARA J. L. M. (1991): Inhibition of the interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood, 78, 1915-1918.
12. MISHELL R. I. and DUTTON R. W. (1967): Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med., 236, 423-442.
13. NAJJAR V. A. (1983): Tuftsin, a natural activator of phagocyte cells: An overwiev. Ann. NY Acad. Sci., 419, 1-11.
14. SCHREUDER H. A., RONDEAU J. M., TARDIF C., SOFFIENTINI A., SARUBBI E., AKESON A., BOWLIN T. L., YANOFSKY S. and BARRETT R. W. (1995): Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline. Eur. J. Biochem., 227, 838-847.
15. SCHREUDER H., TARDIF C., TRUMP-KALLMEYER S., SOFFIENTINI A., SARUBBI E., AKESON A., BOWLIN T., YANOFSKY S. and BARRET R. W. (1997): A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature, 386, 194-200.
16. SIEMION I. Z., SŁOŃ J., SPIEGEL K. and WIECZOREK Z. (1991): The evidence on the possible iaterlcukin-1α-tuftsin competition. Arch. Immunol. Ther. Exp., 39, 605-611.
17. TWIST V. W. and BARNES R. D. (1973): Popliteal lymph node weight gain assay for geraft-versus-host reactivity in mice. Transplantation, 15, 182-185.
18. VIGERS G. P. A., ANDERSON L. J., CAFFES P. and BRANDHUBER B. J. (1997): Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β. Nature, 386, 190-194.
19. WIECZOREK Z., BENGTSSON B., TROJNAR J. and SIEMION I. Z. (1991): Immunosuppressive activity of cyclolinopeptide A. Pept. Res., 4, 275-283.
20. WIECZOREK Z., KLUCZYK A., SŁOŃ-USAKIEWICZ J. J. and SIEMION I. Z. (1997): A hexapeptide VTKFYF from C-terminal part of interleukin-1 receptor antagonist, an inhibitor of IL-1 - IL-1 receptor interaction. Pol. J. Pharmacol., 49, 107-117.
21. WIECZOREK Z., ZIMECKI M., SŁOŃ J. J. and SIEMION I. Z. (1994): The immunomodulatory activity of tetra- and tripeptides of tuftsin-kentsin group. Peptides, 15, 215-221.